Cita APA

Kuemmerle-Deschner, J. B., Ramos, E., Blank, N., Roesler, J., Felix, S. D., Jung, T., . . . Rordorf, C. (2011). Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). BioMed Central.

Chicago Style Citation

Kuemmerle-Deschner, Jasmin B., et al. Canakinumab (ACZ885, a Fully Human IgG1 Anti-IL-1β MAb) Induces Sustained Remission in Pediatric Patients With Cryopyrin-associated Periodic Syndrome (CAPS). BioMed Central, 2011.

Cita MLA

Kuemmerle-Deschner, Jasmin B., et al. Canakinumab (ACZ885, a Fully Human IgG1 Anti-IL-1β MAb) Induces Sustained Remission in Pediatric Patients With Cryopyrin-associated Periodic Syndrome (CAPS). BioMed Central, 2011.